Rice University

Mallard Bay operates an online marketplace designed for sportsmen seeking to book reliable hunting and fishing experiences. The platform allows users to discover and compare guided trips, facilitating secure payment processing and connecting clients with reputable guides and outfitters. Additionally, Mallard Bay offers back-office solutions that assist these services in showcasing their offerings, managing bookings, and processing payments. This comprehensive approach enables outdoor enthusiasts to easily access and enjoy their adventures in a streamlined manner.

TransCrypts is a platform designed to assist Human Resource Departments in automating the issuance of employment and income verification documents. By utilizing blockchain technology, TransCrypts streamlines the creation and distribution of these documents, delivering them directly to employees on a monthly basis. This innovative approach not only enhances compliance with verification requirements but also empowers employees with greater control over their work-related information. The platform aims to alleviate the administrative burdens faced by HR departments, ultimately saving time and resources.

RANDIAN LLC is an innovative company based in Sherman Oaks, California, that offers an interactive shopping network designed to enhance the viewing experience of shows and videos. By integrating a patented platform with e-commerce capabilities, RANDIAN allows users to engage with content while shopping for clothing worn by their favorite characters. Viewers can click on items to access descriptions and add them to their shopping cart, creating a seamless blend of entertainment and retail. This platform not only benefits consumers but also provides valuable insights to brands and content creators about audience behavior, ultimately driving direct sales and transforming traditional advertising methods in the digital landscape.

OncoResponse Inc. is a Houston-based immuno-oncology company focused on discovering innovative cancer therapies through its proprietary human antibody platform. The company specializes in identifying fully human monoclonal antibodies that target high-value immuno-oncology targets, particularly those associated with immunosuppressive myeloid biology. By exploring the adaptive immune responses of cancer patients who have successfully undergone checkpoint inhibition, OncoResponse aims to develop therapeutic antibodies that can mitigate tumor microenvironment immunosuppression and enhance immune activation. This approach seeks to transform cold tumors into hot tumors, thereby improving treatment outcomes for cancer patients.

Medical Magnesium specializes in developing metallic bioabsorbable implants specifically designed for orthopedic and trauma surgery. These innovative implants are both mechanically stable and physiologically degradable, allowing them to dissolve after fracture healing, which eliminates the need for subsequent metal removal surgeries. The company aims to provide tailor-made, highly functional magnesium-based solutions that enhance surgical outcomes and streamline recovery processes for patients. Originating from RWTH Aachen University, Medical Magnesium leverages interdisciplinary research in engineering and medicine to create advanced implant technologies. The implants not only stabilize fracture healing but also release nutrients that aid in regrowing the natural bone structure, ultimately improving patient care and recovery times in clinical settings.

OncoResponse Inc. is a Houston-based immuno-oncology company focused on discovering innovative cancer therapies through its proprietary human antibody platform. The company specializes in identifying fully human monoclonal antibodies that target high-value immuno-oncology targets, particularly those associated with immunosuppressive myeloid biology. By exploring the adaptive immune responses of cancer patients who have successfully undergone checkpoint inhibition, OncoResponse aims to develop therapeutic antibodies that can mitigate tumor microenvironment immunosuppression and enhance immune activation. This approach seeks to transform cold tumors into hot tumors, thereby improving treatment outcomes for cancer patients.